Onvansertib + Paclitaxel In TNBC
Public ClinicalTrials.gov record NCT05383196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
Study identification
- NCT ID
- NCT05383196
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Antonio Giordano, MD
- Other
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
- Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
- Inflammatory Breast Cancer
- Invasive Breast Cancer
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- Unresectable Breast Carcinoma
Interventions
- Onvansertib Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2022
- Primary completion
- Dec 14, 2026
- Completion
- Feb 14, 2029
- Last update posted
- Feb 10, 2026
2022 – 2029
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconness Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05383196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05383196 live on ClinicalTrials.gov.